ReviewMelanoma management2020
Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review.
Review in Melanoma management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Intraoperative Margin Control in Eyelid Tumor Surgery: Current Standards, Imaging Advances, and Emerging Techniques.Current oncology (Toronto, Ont.) · 2026Review
- Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy.Molecules (Basel, Switzerland) · 2026Review
- The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma.Frontiers in immunology · 2026Article
- High Incidence of Isolated Tumor Cells in Sentinel Node Biopsies of Thin Melanomas: A Potential Factor in the Paradoxical Prognosis of Stage IIIA Cutaneous Melanoma?Diagnostics (Basel, Switzerland) · 2024Article
- Caffeine reduces viability, induces apoptosis, inhibits migration and modulates the CD39/CD73 axis in metastatic cutaneous melanoma cells.Purinergic signalling · 2024Article
- Pharmacological Property and Cytotoxic Effect Showing Antiproliferative Potency in Human Melanoma Cell Lines (A375) ofAntioxidants (Basel, Switzerland) · 2023Article
- Temporal Recurrence of Cutaneous Melanoma: Analysis of a Case Series.The Journal of clinical and aesthetic dermatology · 2023Article
- Comprehensive analysis of necroptotic patterns and associated immune landscapes in individualized treatment of skin cutaneous melanoma.Scientific reports · 2023Article
- Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.Advances in therapy · 2023Article
- Fatty Acid Metabolism-Related lncRNAs are Potential Biomarkers for Predicting Prognoses and Immune Responses in Patients with Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2023Article
- Proposing a hybrid technique of feature fusion and convolutional neural network for melanoma skin cancer detection.Journal of pathology informatics · 2023Article
- Identification and validation of a ferroptosis-related gene signature for predicting survival in skin cutaneous melanoma.Cancer medicine · 2022Article
- Necroptosis-associated classification combined with tumor microenvironment characteristic analysis of cutaneous melanoma.Scientific reports · 2022Article
- PGAM5: A necroptosis gene associated with poor tumor prognosis that promotes cutaneous melanoma progression.Frontiers in oncology · 2022Article
- Chemical and Biological Characterization of the Anticancer Potency ofPlants (Basel, Switzerland) · 2021Article
- Broad-Spectrum Antibiotic Use and Disease Progression in Early-Stage Melanoma Patients: A Retrospective Cohort Study.Cancers · 2021Article
- Article
- Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.Cancers · 2021Article
- Defining the Criteria for Reflex Testing forCancers · 2021Review
- Establishment and validation of an autophagy-related prognostic signature for survival predicting in cutaneous melanoma.American journal of cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimManagement of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM. MATERIALS &
methodsSystematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers. RESULTS &
conclusionOf 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.